← FDA DRUG APPROVALS

FDA ANDA · ANDA040327

ORPHENADRINE CITRATE

Sponsor: SANDOZ

APPLICATION
ANDA040327
TYPE
ANDA
ORIGINAL APPROVAL
2000-02-15
LATEST ACTION
2010-03-30
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

ORPHENADRINE CITRATEPrescription
ORPHENADRINE CITRATE 100MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2010-03-30Labeling · Supplement 12AP
2002-05-08Manufacturing (CMC) · Supplement 3AP
2001-05-30Manufacturing (CMC) · Supplement 2AP
2000-02-15OriginalLetterAP
2000-02-15Manufacturing (CMC) · Supplement 1AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →